drugset
drugset / Trial / NCT03895697

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

NCT03895697 ↗

Phase 3 Completed 92 enrolled Zealand Pharma
RandomizedCrossoverQuadruple-blindTreatment

Summary

A randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus (T1DM)

Timeline

Start
2019-03-26
Primary completion
2019-07-30
Completion
2019-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasiglucagon Peptide — Subcutaneous

Indications

hypoglycemia type 1 diabetes mellitus